Recruiting EARLY_PHASE1 Tauopathies

New treatment option for Tauopathies

Official title Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

ClinicalTrials.gov ID: NCT06932809

What this study is testing

What is 18F-JSS20-183A PET?

18F-JSS20-183A PET is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for tauopathies.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and healthy controls.
  • Phase 1: an early, usually small safety study

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 40 to 85

You may be able to join if

  • Patients in all cohorts will be male or female adults from 40 to 85 years of age.
  • Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this...

You likely can't join if

  • Females who are pregnant or breast feeding will be excluded, a urine pregnancy test will be performed in women of child-bearing potential prior to...
  • Forms of parkinsonism other than PSP-RS, and PD as defined above
  • History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported
  • Contraindications or inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or...
  • Contraindication to MRI, such as non-compatible implanted medical device
  • Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or...

The study team makes the final eligibility decision.

Where it's taking place

  • San Francisco, California, United States
  • Philadelphia, Pennsylvania, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 40 years to 85 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include San Francisco, California, United States; Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.